Carta científico-clínica
Morfea en una paciente con psoriasis en tratamiento con ustekinumab: ¿coexistencia o efecto adverso?
Morphea in a Patient With Psoriasis on Treatment With Ustekinumab: Comorbidity or Adverse Effect?
O. Corral Magaña, J. Escalas Taberner
, M.M. Escudero Góngora, A. Giacaman Contreras
Autor para correspondencia
Servicio de Dermatología, Hospital Universitario Son Espases, Palma de Mallorca, Islas Baleares, España
Leído
5581
Vecesse ha leído el artículo
1961
Total PDF
3620
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 6 | 55 | 39 | 94 |
| 2025 5 | 122 | 48 | 170 |
| 2025 4 | 91 | 27 | 118 |
| 2025 3 | 84 | 15 | 99 |
| 2025 2 | 106 | 35 | 141 |
| 2025 1 | 82 | 24 | 106 |
| 2024 12 | 82 | 30 | 112 |
| 2024 11 | 74 | 66 | 140 |
| 2024 10 | 45 | 36 | 81 |
| 2024 9 | 63 | 20 | 83 |
| 2024 8 | 76 | 56 | 132 |
| 2024 7 | 87 | 20 | 107 |
| 2024 6 | 100 | 24 | 124 |
| 2024 5 | 43 | 28 | 71 |
| 2024 4 | 60 | 23 | 83 |
| 2024 3 | 65 | 30 | 95 |
| 2024 2 | 46 | 30 | 76 |
| 2024 1 | 46 | 29 | 75 |
| 2023 12 | 46 | 16 | 62 |
| 2023 11 | 54 | 44 | 98 |
| 2023 10 | 49 | 27 | 76 |
| 2023 9 | 36 | 21 | 57 |
| 2023 8 | 34 | 23 | 57 |
| 2023 7 | 70 | 30 | 100 |
| 2023 6 | 45 | 19 | 64 |
| 2023 5 | 77 | 23 | 100 |
| 2023 4 | 58 | 12 | 70 |
| 2023 3 | 95 | 21 | 116 |
| 2023 2 | 62 | 22 | 84 |
| 2022 1 | 39 | 27 | 66 |
| 2022 12 | 60 | 29 | 89 |
| 2022 11 | 50 | 38 | 88 |
| 2022 10 | 64 | 44 | 108 |
| 2022 9 | 41 | 43 | 84 |
| 2022 8 | 49 | 53 | 102 |
| 2022 7 | 51 | 31 | 82 |
| 2022 6 | 44 | 25 | 69 |
| 2022 5 | 46 | 42 | 88 |
| 2022 4 | 60 | 24 | 84 |
| 2022 3 | 33 | 52 | 85 |
| 2022 2 | 39 | 22 | 61 |
| 2021 1 | 56 | 36 | 92 |
| 2021 12 | 43 | 37 | 80 |
| 2021 11 | 40 | 23 | 63 |
| 2021 10 | 33 | 56 | 89 |
| 2021 9 | 29 | 37 | 66 |
| 2021 8 | 40 | 31 | 71 |
| 2021 7 | 32 | 33 | 65 |
| 2021 6 | 41 | 35 | 76 |
| 2021 5 | 41 | 44 | 85 |
| 2021 4 | 107 | 46 | 153 |
| 2021 3 | 67 | 30 | 97 |
| 2021 2 | 70 | 29 | 99 |
| 2020 1 | 42 | 30 | 72 |
| 2020 12 | 33 | 14 | 47 |
| 2020 11 | 32 | 20 | 52 |
| 2020 10 | 52 | 25 | 77 |
| 2020 9 | 47 | 18 | 65 |
| 2020 8 | 43 | 15 | 58 |
| 2020 7 | 22 | 21 | 43 |
| 2020 6 | 49 | 25 | 74 |
| 2020 5 | 30 | 24 | 54 |
| 2020 4 | 10 | 16 | 26 |
| 2020 3 | 28 | 14 | 42 |
| 2020 2 | 2 | 0 | 2 |
| 2020 1 | 2 | 0 | 2 |
| 2019 11 | 4 | 0 | 4 |
| 2019 7 | 1 | 0 | 1 |
| 2019 5 | 2 | 3 | 5 |
| 2019 4 | 2 | 0 | 2 |
| 2018 12 | 2 | 0 | 2 |
| 2018 11 | 7 | 0 | 7 |
| 2018 9 | 3 | 0 | 3 |
| 2018 8 | 0 | 1 | 1 |
| 2018 6 | 0 | 1 | 1 |
| 2018 5 | 3 | 0 | 3 |
| 2018 4 | 1 | 1 | 2 |
| 2018 2 | 6 | 2 | 8 |
| 2018 1 | 6 | 3 | 9 |
| 2017 12 | 8 | 0 | 8 |
| 2017 11 | 11 | 0 | 11 |
| 2017 10 | 4 | 0 | 4 |
| 2017 9 | 9 | 2 | 11 |
| 2017 8 | 1 | 1 | 2 |
| 2017 7 | 11 | 3 | 14 |
| 2017 6 | 19 | 10 | 29 |
| 2017 5 | 0 | 2 | 2 |
| 2017 3 | 0 | 1 | 1 |
| 2017 2 | 0 | 2 | 2 |
| 2016 1 | 0 | 2 | 2 |
Mostrar todo
